Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Determinants of survival following pelvic exenteration for primary rectal cancer.

Radwan RW, Jones HG, Rawat N, Davies M, Evans MD, Harris DA, Beynon J; Swansea Pelvic Oncology Group..

Br J Surg. 2015 Sep;102(10):1278-84. doi: 10.1002/bjs.9841. Epub 2015 Jun 11.

PMID:
26095525
2.

Multivisceral resection for primary locally advanced rectal carcinoma.

Harris DA, Davies M, Lucas MG, Drew P, Carr ND, Beynon J; Swansea Pelvic Oncology Group..

Br J Surg. 2011 Apr;98(4):582-8. doi: 10.1002/bjs.7373. Epub 2010 Dec 24.

PMID:
21656723
3.

Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial.

Rustin GJ, van der Burg ME, Griffin CL, Guthrie D, Lamont A, Jayson GC, Kristensen G, Mediola C, Coens C, Qian W, Parmar MK, Swart AM; MRC OV05.; EORTC 55955 investigators..

Lancet. 2010 Oct 2;376(9747):1155-63. doi: 10.1016/S0140-6736(10)61268-8.

4.

Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis.

ASTEC/EN.5 Study Group., Blake P, Swart AM, Orton J, Kitchener H, Whelan T, Lukka H, Eisenhauer E, Bacon M, Tu D, Parmar MK, Amos C, Murray C, Qian W.

Lancet. 2009 Jan 10;373(9658):137-46. doi: 10.1016/S0140-6736(08)61767-5. Epub 2008 Dec 16. Review.

5.

Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study.

ASTEC study group., Kitchener H, Swart AM, Qian Q, Amos C, Parmar MK.

Lancet. 2009 Jan 10;373(9658):125-36. doi: 10.1016/S0140-6736(08)61766-3. Epub 2008 Dec 16. Erratum in: Lancet. 2009 May 23;373(9677):1764.

6.

Use of a leucocyte filter to remove tumour cells from intra-operative cell salvage blood.

Catling S, Williams S, Freites O, Rees M, Davies C, Hopkins L.

Anaesthesia. 2008 Dec;63(12):1332-8. doi: 10.1111/j.1365-2044.2008.05637.x.

7.

A steroid-cell tumor of the ovary resulting in massive androgen excess early in the gonadol steroidogenic pathway.

Stephens JW, Fielding A, Verdaguer R, Freites O.

Gynecol Endocrinol. 2008 Sep;24(9):502-4. doi: 10.1080/09513590802295478. Erratum in: Gynecol Endocrinol. 2012 Apr;28(4):340.

PMID:
18958769
8.

A steroid-cell tumor of the ovary resulting in massive androgen excess early in the gonadol steroidogenic pathway.

Stephens JW, Fielding A, Verdaguer R, Freites O.

Gynecol Endocrinol. 2008 Mar;24(3):151-3. doi: 10.1080/09513590801917106. Review. Erratum in: Gynecol Endocrinol. 2012 Apr;28(4):340.

PMID:
18335330
9.

How innocent is the vaginal pessary? Two cases of vaginal cancer associated with pessary use.

Jain A, Majoko F, Freites O.

J Obstet Gynaecol. 2006 Nov;26(8):829-30. No abstract available.

PMID:
17130056
10.
11.

Exenterative pelvic surgery--eleven year experience of the Swansea Pelvic Oncology Group.

Nguyen DQ, McGregor AD, Freites O, Carr ND, Beynon J, El-Sharkawi AM, Lucas MG.

Eur J Surg Oncol. 2005 Dec;31(10):1180-4. Epub 2005 Aug 26.

PMID:
16126362
12.

Omentopexy for reconstruction of the perineum following a radical vulvectomy: a case report.

Shylasree TS, Karandikar S, Freites O, McGregor I, Carr ND.

Int J Gynecol Cancer. 2004 Nov-Dec;14(6):1122-5.

PMID:
15571619
13.
14.

Clinical experience with cell salvage in obstetrics: 4 cases from one UK centre.

Catling SJ, Freites O, Krishnan S, Gibbs R.

Int J Obstet Anesth. 2002 Apr;11(2):128-34.

PMID:
15321566

Supplemental Content

Loading ...
Support Center